Zydus Lifesciences Ltd. announced that it has received final approval from the US Food and Drug Administration (USFDA) to market its generic version of Triazolam tablets, which are used to treat insomnia in the short term.

The approval granted by the USFDA is to market Triazolam tablets of strengths 0.125 mg and 0.25 mg, the company said in a regulatory filing.

The medicine is used on a short-term basis to treat insomnia—difficulty falling asleep or staying asleep.

Click for ore articles on USFDA

It works by slowing activity in the brain to allow sleep.

It will be manufactured at the group's formulation manufacturing facility at Moraiya, Ahmedabad, the company said.

Triazolam tablets had annual sales of USD 11.7 million in the US, the company said, citing IQVIA MAT September 2022 data.

Other drugs approval by USFDA

USFDA approves this monoclonal antibody to treat multiple sclerosis

USFDA gives final approval to this breast cancer injection

USFDA gives approval for Fulvestrant injection

USFDA gives approval for this Genetic Disorder drug

USFDA gives approval for Lymphoma Therapy

USFDA gives approval for Pregabalin capsules

Antibiotics need to be developed urgently for newborns: Experts

Pharma companies told to ensure drug stocks

Drug recall: 4 lots of Quinapril Tablets recalled due to this reason

USFDA approves this monoclonal antibody to treat multiple sclerosis

IPC launches 10 new impurities standards

CDSCO and States starts joint inspections of Drug Manufacturing Units

DCGI calls for registering (MDTLs) Medical Devices Testing Laboratories

Confession in criminal proceedings: Ground for conviction ?

Registration for sale of Medical Devices: Procedure and conditions

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/12/31/usfda-gives-final-approval-for-this-insomnia-drug/